Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.
Dréan A, Goldwirt L, Verreault M, Canney M, Schmitt C, Guehennec J, Delattre JY, Carpentier A, Idbaih A. Dréan A, et al. Expert Rev Neurother. 2016 Nov;16(11):1285-1300. doi: 10.1080/14737175.2016.1202761. Epub 2016 Jul 4. Expert Rev Neurother. 2016. PMID: 27310463 Review.
Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
Dréan A, Lemaire N, Bouchoux G, Goldwirt L, Canney M, Goli L, Bouzidi A, Schmitt C, Guehennec J, Verreault M, Sanson M, Delattre JY, Mokhtari K, Sottilini F, Carpentier A, Idbaih A. Dréan A, et al. J Neurooncol. 2019 Aug;144(1):33-41. doi: 10.1007/s11060-019-03204-0. Epub 2019 Jun 13. J Neurooncol. 2019. PMID: 31197598 Free article.
Current Management Practices for Endometrial Cancer (EC) in the UK: A National Healthcare Professional Survey (KNOW-EC).
George A, Herbertson RA, Stillie A, McCormack S, Drean AM, Wesselbaum A, Hudson E, Miles T, Ryan NAJ, Maxwell H, Le Treust L, McCormack M. George A, et al. Among authors: drean am. Clin Oncol (R Coll Radiol). 2024 Nov;36(11):e448-e455. doi: 10.1016/j.clon.2024.05.017. Epub 2024 May 31. Clin Oncol (R Coll Radiol). 2024. PMID: 39048405 Free article.
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ. Pettitt SJ, et al. Among authors: drean a. Nat Commun. 2018 May 10;9(1):1849. doi: 10.1038/s41467-018-03917-2. Nat Commun. 2018. PMID: 29748565 Free PMC article.
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ. Dréan A, et al. Mol Cancer Ther. 2017 Sep;16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098. Epub 2017 Jun 15. Mol Cancer Ther. 2017. PMID: 28619759 Free PMC article.
PARP inhibitor combination therapy.
Dréan A, Lord CJ, Ashworth A. Dréan A, et al. Crit Rev Oncol Hematol. 2016 Dec;108:73-85. doi: 10.1016/j.critrevonc.2016.10.010. Epub 2016 Oct 31. Crit Rev Oncol Hematol. 2016. PMID: 27931843 Review.